-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the Heilongjiang Centralized Drug Purchasing Network issued a notice on the implementation of the results of the price linkage of drugs linked to the central procurement in Heilongjiang Province and a notice on the implementation of the linked results of drug prices linked to the Internet
.
The notice shows that in order to further reduce drug prices, on the basis of ensuring the availability of drugs, the bureau has carried out online price linkage work
.
According to the contents of the annex to the notice, a total of 16,593 drugs are subject to linked prices, including amoxicillin sodium for injection, acyclovir for injection, betamethasone sodium phosphate injection, docetaxel injection,
etc.
Judging from the price reduction rate, there are many varieties with significant price reductions, such as: Fufang Yancaisu Tablets of Hunan Fuxing Feige Pharmaceutical Co.
, Ltd.
, and Compound Snow Lotus Capsules of Sinopharm Xinjiang Pharmaceutical Co.
, Ltd.
, all of which have dropped by more than 90%; Jiangxi Nanchang The compound fresh bamboo liquor of Jisheng Pharmaceutical Co.
, Ltd.
decreased by 85.
51%; the 0.
5g*1 bottle/bottle of acyclovir for injection by Hubei Hope Pharmaceutical Co.
, Ltd.
decreased by 75.
61%; Wuhan Pusheng Pharmaceutical Co.
, Ltd.
was 0.
25% The price reduction rate of acyclovir for g*1 bottle (support)/bottle (support) is 62.
25%; the price reduction rate of azlocillin sodium for injection of 1.
0g*1 bottle/bottle of Sichuan Pharmaceutical Preparation Co.
, Ltd.
is 60.
2%,
etc.
In addition, many varieties with a decline are large varieties with a level of 1 billion, such as docetaxel
.
According to data from Minet.
com, the sales of terminal docetaxel in Chinese public medical institutions remained above 4 billion yuan in 2019
.
The domestic market share is mainly occupied by Hengrui, the original research Sanofi, Qilu Pharmaceutical, etc.
, and the market competition is becoming increasingly fierce
.
From the perspective of competition, Hengrui Medicine occupies more than 40% of the market share, followed by Sanofi with more than 30%
.
The companies that have reviewed include Hengrui Pharmaceuticals, Huiyu Pharmaceuticals, Chia Tai Tianqing, Qilu Pharmaceuticals, Yangzijiang Pharmaceuticals, Meda Konkale Pharmaceuticals, Osaikang and several others
.
In the fifth round of national procurement, Hengrui Pharmaceutical, Chia Tai Tianqing, Yangzijiang Pharmaceutical, Qilu Pharmaceutical, Huiyu Pharmaceutical, and Osaikang Pharmaceutical won the bid, and the original research company Sanofi was eliminated. .
In the list of drugs subject to the linkage price this time, the Docetaxel injection of Chia Tai Tianqing 1ml:20mg*1 bottle/box dropped by 50.
44%; Hengrui products of the same specification dropped from RMB 1,051.
5 to RMB 910.
0, a drop.
It was 13.
46%, and Osaikang Pharmaceuticals dropped by 14.
21%; Huiyu Pharmaceutical 4ml: 80mg*1 bottle/box of products dropped by more than 30%; Sanofi (Hangzhou) 0.
5ml: 20mg*1 bottle/box (attached separately 1 bottle of solvent 1.
5ml)*1 bottle/box specification is reduced by 30%
.
In addition, the price of the products of Meda Konkale Pharmaceuticals has also declined
.
The notice clarifies that the price of linked drugs will be implemented from March 21, 2022
.
During the transition period, medical institutions should do a good job in the digestion of drug inventory, and do a good job in the return, exchange, price adjustment and other related work of inventory drugs
.
From the date of implementation, medical institutions must purchase medicines at the new prices on the platform
.
There are 16,488 drugs that have not been traded within the three-year linkage plan, including cefradine capsules, sodium chloride injection, gatifloxacin sodium chloride injection and other varieties, involving Kelun Pharmaceutical, Livzon Group, CSPC, China Resources There are a large number of local pharmaceutical companies such as Sanjiu, and many multinational companies such as ALK-Abello A/S in Denmark
.
According to the notice, this batch of drugs will be withdrawn from the centralized drug procurement platform of Heilongjiang Province, and relevant drugs will no longer be accepted on the Internet within two years after withdrawal
.
In addition, the annex shows that there are 6,541 drugs that have applied for withdrawal from the network, 6,128 that have not responded to the linkage, and 433 regulated drugs have been appealed and challenged
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
The notice shows that in order to further reduce drug prices, on the basis of ensuring the availability of drugs, the bureau has carried out online price linkage work
.
According to the contents of the annex to the notice, a total of 16,593 drugs are subject to linked prices, including amoxicillin sodium for injection, acyclovir for injection, betamethasone sodium phosphate injection, docetaxel injection,
etc.
Judging from the price reduction rate, there are many varieties with significant price reductions, such as: Fufang Yancaisu Tablets of Hunan Fuxing Feige Pharmaceutical Co.
, Ltd.
, and Compound Snow Lotus Capsules of Sinopharm Xinjiang Pharmaceutical Co.
, Ltd.
, all of which have dropped by more than 90%; Jiangxi Nanchang The compound fresh bamboo liquor of Jisheng Pharmaceutical Co.
, Ltd.
decreased by 85.
51%; the 0.
5g*1 bottle/bottle of acyclovir for injection by Hubei Hope Pharmaceutical Co.
, Ltd.
decreased by 75.
61%; Wuhan Pusheng Pharmaceutical Co.
, Ltd.
was 0.
25% The price reduction rate of acyclovir for g*1 bottle (support)/bottle (support) is 62.
25%; the price reduction rate of azlocillin sodium for injection of 1.
0g*1 bottle/bottle of Sichuan Pharmaceutical Preparation Co.
, Ltd.
is 60.
2%,
etc.
In addition, many varieties with a decline are large varieties with a level of 1 billion, such as docetaxel
.
According to data from Minet.
com, the sales of terminal docetaxel in Chinese public medical institutions remained above 4 billion yuan in 2019
.
The domestic market share is mainly occupied by Hengrui, the original research Sanofi, Qilu Pharmaceutical, etc.
, and the market competition is becoming increasingly fierce
.
From the perspective of competition, Hengrui Medicine occupies more than 40% of the market share, followed by Sanofi with more than 30%
.
The companies that have reviewed include Hengrui Pharmaceuticals, Huiyu Pharmaceuticals, Chia Tai Tianqing, Qilu Pharmaceuticals, Yangzijiang Pharmaceuticals, Meda Konkale Pharmaceuticals, Osaikang and several others
.
In the fifth round of national procurement, Hengrui Pharmaceutical, Chia Tai Tianqing, Yangzijiang Pharmaceutical, Qilu Pharmaceutical, Huiyu Pharmaceutical, and Osaikang Pharmaceutical won the bid, and the original research company Sanofi was eliminated. .
In the list of drugs subject to the linkage price this time, the Docetaxel injection of Chia Tai Tianqing 1ml:20mg*1 bottle/box dropped by 50.
44%; Hengrui products of the same specification dropped from RMB 1,051.
5 to RMB 910.
0, a drop.
It was 13.
46%, and Osaikang Pharmaceuticals dropped by 14.
21%; Huiyu Pharmaceutical 4ml: 80mg*1 bottle/box of products dropped by more than 30%; Sanofi (Hangzhou) 0.
5ml: 20mg*1 bottle/box (attached separately 1 bottle of solvent 1.
5ml)*1 bottle/box specification is reduced by 30%
.
In addition, the price of the products of Meda Konkale Pharmaceuticals has also declined
.
The notice clarifies that the price of linked drugs will be implemented from March 21, 2022
.
During the transition period, medical institutions should do a good job in the digestion of drug inventory, and do a good job in the return, exchange, price adjustment and other related work of inventory drugs
.
From the date of implementation, medical institutions must purchase medicines at the new prices on the platform
.
There are 16,488 drugs that have not been traded within the three-year linkage plan, including cefradine capsules, sodium chloride injection, gatifloxacin sodium chloride injection and other varieties, involving Kelun Pharmaceutical, Livzon Group, CSPC, China Resources There are a large number of local pharmaceutical companies such as Sanjiu, and many multinational companies such as ALK-Abello A/S in Denmark
.
According to the notice, this batch of drugs will be withdrawn from the centralized drug procurement platform of Heilongjiang Province, and relevant drugs will no longer be accepted on the Internet within two years after withdrawal
.
In addition, the annex shows that there are 6,541 drugs that have applied for withdrawal from the network, 6,128 that have not responded to the linkage, and 433 regulated drugs have been appealed and challenged
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
